Uric acid reduction rectifies prehypertension in obese adolescents

Area of Science:

• Cardiovascular Research
• Metabolic Disease Research
• Pediatric Hypertension

Background:

• Epidemiologic studies and animal models suggest a link between uric acid and essential hypertension.
• The role of uric acid as a causative factor versus a surrogate marker in hypertension remains debated.
• Preliminary trials in children indicate uric acid's involvement in hypertension development.

Purpose of the Study:

• To investigate if uric acid is a causative mediator of increased blood pressure (BP) and impaired vascular compliance.
• To determine the efficacy of urate-lowering therapies in reducing BP in prehypertensive adolescents.

Main Methods:

• A randomized, double-blinded, placebo-controlled trial was conducted.
• Prehypertensive, obese adolescents (aged 11-17 years) were enrolled.
• Participants were randomized to receive allopurinol, probenecid, or a placebo.

Main Results:

• Urate-lowering therapy led to a significant reduction in BP.
• Systolic BP decreased by 10.2 mm Hg and diastolic BP by 9.0 mm Hg in treated patients.
• Systemic vascular resistance was also significantly reduced with urate-lowering therapy.

Conclusions:

• Uric acid is a causative factor for increased blood pressure in adolescents with prehypertension.
• Urate-lowering therapy can effectively mitigate elevated BP and improve vascular function in this population.
• These findings support targeting uric acid reduction for managing prehypertension in adolescents.